Advanced Metastatic Triple-Negative Breast Cancer (TNBC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Advanced Metastatic Triple-Negative Breast Cancer (TNBC) Market Outlook
Thelansis’s “Advanced Metastatic
Triple-Negative Breast Cancer (TNBC) Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2024 To 2034" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Advanced
Metastatic Triple-Negative Breast Cancer (TNBC) treatment modalities options
for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and
China).
Advanced
Metastatic Triple-Negative Breast Cancer (TNBC) Overview
Advanced
Metastatic Triple-Negative Breast Cancer (TNBC) is a distinct and immensely
complex form of breast cancer. Among all subtypes of breast cancers, TNBC has a
comparatively high rate of relapse, a high rate of distant metastasis, and poor
overall survival after standard chemotherapy. TNBC is a heterogeneous disease
encompassing a variety of biomarkers or genomic signatures; it accounts for 12%
of all breast cancers in the USA. 1- and 2- year survival rates are 75% and
55%, respectively. Prognosis is poor in the advanced stages – median survival
of 13.3 months following diagnosis of metastatic TNBC. •Emerging therapies are
expected to drive patient stratification for biomarker-defined and
pathway-specific (subtyping) patient subgroups – an opportunity for a novel
agent in relevant specific segments. TNBC is a clinicopathologic, not intrinsic
(genomically defined) subgroup, as neither overexpressing ER and PR nor being
HER2+ (IHC and/or FISH). Neither hormonal (endocrine) nor HER2-targeted
therapies are indicated Potential for FastTrack/ breakthrough designation with
promising outcomes in the biomarker-driven patient segment; Several PARP
inhibitors are in trials; veliparib+carboplatin followed by chemotherapy showed
pCR: 52% vs. 26% (chemotherapy alone) 40% of TNBC show overexpression of GPNMB;
unusual activity with glembatumumab, a GPNMB-targeting AD Biomarker-driven
segments have been identified within TNBC, with POC. A better understanding of
these would enable personalized treatment with improved patient outcomes. p53,
PTEN, and PIK3CA are most frequently mutated in TNBC (>10%).
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment